Friday, June 07, 2024 8:34:00 AM
I hope so Attila. I am sitting on a boat load of cash. I can either:
A) Buy more Anavex as its MC is so low it may be the best deal out there right now for a small Bio. If they crack the Alzheimer's nut, the stock will instantly go up to a $10-20B MC, as its one of the largest markets out there. They are preparing to file for Alz EU approval based on conversation with the EU for their lead compound 2-73.
B) By more NWBO. Smaller market for now and I already own way too much. I dont like the Managment Team
C) Sit on cash as a falling market will take ALL equites for a deep-dive. Look for deals after the dust settles and we are in a period of MAX fear. The higher the rise, the steeper the fall. Its been a great ride, but all great rides come to a end.
D) spend the cash on things I always wanted, and a give some to charity.
Decisions like this are always tough.
A) Buy more Anavex as its MC is so low it may be the best deal out there right now for a small Bio. If they crack the Alzheimer's nut, the stock will instantly go up to a $10-20B MC, as its one of the largest markets out there. They are preparing to file for Alz EU approval based on conversation with the EU for their lead compound 2-73.
B) By more NWBO. Smaller market for now and I already own way too much. I dont like the Managment Team
C) Sit on cash as a falling market will take ALL equites for a deep-dive. Look for deals after the dust settles and we are in a period of MAX fear. The higher the rise, the steeper the fall. Its been a great ride, but all great rides come to a end.
D) spend the cash on things I always wanted, and a give some to charity.
Decisions like this are always tough.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
